Abstracts tagged "interferons and treatment"

Abstract Number: 770 • ACR/ARHP Annual Meeting 2016
Introducing a Novel SLE-Specific IFN-I Inhibitor CNTO 6358: Laying the Groundwork for Precision Medicine in Lupus
Jarrat Jordan¹, Matteo Cesaroni¹, Jessica Schreiter¹, Chichi Huang², Tanesha Cash-Mason³, Marc Chevrier¹ and Jacqueline Benson¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Biologics Research, Janssen Research and Development, LLC., Spring House, PA, ³Cardiovascular and Metabolism Research, Janssen Research and Development, LLC., Spring House, PA
Background/Purpose: The type I interferon (IFN-I) family of cytokines signal through a ubiquitously expressed heterodimeric receptor (IFNAR) composed of IFNAR1 and the high-affinity binding chain…
Abstract Number: 3229 • ACR/ARHP Annual Meeting 2016
Bone Morphogenetic Protein 6 Receptor Inhibition Restores Salivary Gland Function in a Mouse Model of Primary Sjögren’s Syndrome
Hongen Yin¹, Lovika Kalra¹, Arif Karim¹, Zhennan Lai¹, Maria Guimaro¹, Lauren Aber¹, Bill Swaim¹, Sandra Afione¹, Alexandria Voigt², Cuong Nguyen³, Paul Yu⁴, Donald Bloch⁵ and John A. Chiorini¹, ¹Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ²Department of Pathology and Infectious Diseases, University of Florida, Gainesville, FL, ³Department of Pathology and Infectious Diseases, University of Florida, Bethesda, MD, ⁴Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵Center for Immunology and Inflammatory Diseases and the Division of Rheumatology, Allergy, and Immunology of the Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Methods: Results: Elevated BMP6 was found in 63/80 (78.8%) of pSS patients examined in this study. In humans, ALK2 and ALK3 receptors…
Abstract Number: 1072 • ACR/ARHP Annual Meeting 2015
Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE
Robert W Hoffman¹, Joan T Merrill², Marta E. Marta Alarcón Riquelme³, Michelle Petri⁴, Ernst R Dow⁵, Eric Nantz⁶, Laura K Nisenbaum⁵, Krista M Schroeder⁶, Wendy J Komocsar⁶, Narayanan B Perumal⁵, Matthew D Linnik⁶, Guilherme V Rocha⁶ and Richard E Higgs⁶, ¹Immunology-Medical, Eli Lilly and Company, Indianapolis, IN, ²OMRF, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Eli Lilly and Company, Indiananpolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Elevated Type-I interferon (IFN) signature characterizes at least 50% of adults with SLE and has been associated with autoantibodies and more severe disease in…
Abstract Number: 1608 • ACR/ARHP Annual Meeting 2013
A Phase I Single-Dose Crossover Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy Of AMG 811 (anti-IFN-gamma) In Subjects With Discoid Lupus Erythematosus
Victoria P. Werth¹, David Fiorentino², Stanley B. Cohen³, David Fivenson⁴, Chris Hansen⁵, Steve Zoog⁶, Greg Arnold⁷, Christine Wang⁸, Michael Boedigheimer⁶, Andrew Welcher⁶, James Chung⁶, Barbara Sullivan⁶ and David A. Martin⁹, ¹Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA, ²Dermatology, Stanford University School of Medicine, Redwood City, CA, ³Metroplex Clinical Research Center, Dallas, TX, ⁴David Fivenson, MD, Dermatology, PLLC, Ann Arbor, MI, ⁵University of Utah School of Medicine, Salt Lake City, UT, ⁶Amgen, Thousand Oaks, CA, ⁷Medical Sciences, Amgen, Thousand Oaks, CA, ⁸Biostatistics, Amgen, Thousand Oaks, CA, ⁹Medical Sciences, Amgen, Seattle, WA
Background/Purpose: Discoid Lupus Erythematosus (DLE) is the most common form of chronic cutaneous LE (CCLE) and develops in up to a quarter of SLE patients.…